Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge

NCT07034131 | Not Yet Recruiting

• 1 other identifier: 2025-0064
• Study Type: interventional
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.

Conditions

Osteoporosis Risk; Osteoporosis, Postmenopausal

Outcome Measures

Primary Outcomes (2)

• Osteoporosis Prevention and Awareness Tool (OPAAT) score

  * 30-item questionnaire measuring osteoporosis knowledge * Minimum value = 0, maximum value = 30 * Higher scores indicate a better outcome

  On enrolment and 6-8 weeks post enrolment

• System Usability Scale (SUS)

  * 10-item questionnaire assessing usability * Minimum value = 0, maximum value = 100 * Higher scores mean a better outcome

  6-8 weeks post enrolment

Secondary Outcomes (3)

• Recruitment rate

  over the course of recruitment, estimated 3-4 months

• Retention rate

  6-8 weeks post-enrolment

• Utility rate

  4 weeks

Study Arms (2)

Intervention

EXPERIMENTAL

use of Osteo-Buddy for 4 weeks

Other: Osteo-Buddy; Other: Usual Care

Control

EXPERIMENTAL

usual care - access to digitalised educational materials titled 'Healthy Bones'

Other: Usual Care

Interventions

Osteo-Buddy OTHER

Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with: 1. Evaluating their risk level of osteoporosis 2. Recommending screening and referrals 3. Lifestyle interventions through motivation, education and tailored guidance As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data.

Intervention

Usual Care OTHER

Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'

Control; Intervention

Eligibility Criteria

• Age: 50 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 50 and above
• Medium or high Osteoporosis Self-Assessment Tool for Asians (OSTA) score
• Not undertaken Bone Mineral Density (BMD) scan
• Never been treated with anti-osteoporosis medications such as bisphosphonates (e.g. alendronate, risendronate, ibandronate, zolendronate, pamidronate) or denosumab
• Able to read and speak English
• Currently use and own a smartphone where Osteo-Buddy can be used

You may not qualify if:

• Known terminal illness
• Visual, hearing and/or cognitive impairment or mental illness that renders them unable to provide informed consent

Sponsors & Collaborators

• SingHealth Polyclinics: lead

MeSH Terms

Conditions

Osteoporosis, Postmenopausal

Condition Hierarchy (Ancestors)

Osteoporosis; Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Eunice Lim

  SingHealth Polyclinics

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Eunice Lim

CONTACT

+65 6340 7436; eunice.lim.s.m@singhealth.com.sg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Family Physician

Study Record Dates

• First Submitted: June 13, 2025
• First Posted: June 24, 2025
• Study Start: July 1, 2025
• Primary Completion: March 1, 2026
• Study Completion: March 1, 2026
• Last Updated: July 1, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share